206 results about "Fusion peptide" patented technology

Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods.

Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods that produce high yields (e.g., milligram levels) of purified proteins, thereby yielding sufficient purified product for multiple assays and analyses. The high throughput purification technique is simpler and less expensive than current commercial high throughput purification methods, since it requires only one transfer of purification intermediates to a new multiwell plate.

Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components-the ligand and the lytic peptide-may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

A method of local treatment of specific bone defects such as osteoporosis or bone cysts comprises the step of local administration of a formulation comprising a fusion peptide containing a first domain comprising PTH or BMP 2 or BMP 7, and a second domain comprising a covalently crosslinkable substrate domain; and a material suitable of forming a biodegradable matrix suitable for cellular growth or in-growth, wherein the fusion peptide is covalently linked to the matrix. In one embodiment, the matrix contains one or more contrast agents, and is preferably formed in the absence of a growth factor. The matrix may be used in the treatment of fluid-filled cysts such as Tarlov cysts, ovarian cysts, arachnoid cysts, aneurysmal bone cysts or hepatic cysts.

Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells.

In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide.

The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.

The resulting fusion peptide being exemplified as

• NH2-CD4-GBP130-COOH
• 1-371 201-774

Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection.

The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a polymeric nanoparticle containing a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary peptide utilized in the invention is Mart-1:27-35 peptide.

Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.

An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-Osp borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of OspC.

The present invention provides an improved process for the production of recombinant peptides. In particular, the present invention provides an improved process for the production of recombinant peptides in the form of viral capsid fusion proteins which can be assembled in vivo in plant cell suspension cultures. The invention also includes plasmids, sequences, and plant cells which allow for non-infectious viral capsid fusion peptide production.

Cystatin-based peptide tags, referred to here as inclusion body tags (IBTs), are disclosed useful for the generation of insoluble fusion peptides. The fusion peptides comprise at least one inclusion body tag operably linked to a peptide of interest. Expression of the fusion peptide in a host cell results in a product that is insoluble and contained within inclusion bodies in the cell and/or cell lysate. The inclusion bodies may then be purified and the protein of interest may be isolated after cleavage from the inclusion body tag.

Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components-the ligand and the lytic peptide-may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.

The present invention provides a fusion protein comprising an Fc receptor binding polypeptide and an antigenic polypeptide. The fusion peptide may further comprise a linker sequence or hinge portion which joins the Fc receptor biding polypeptide and the antigenic polypeptide. The Fc receptor binding polypeptide typically comprises the CH2 constant domain of a human IgG immunoglobulin. The antigenic polypeptide can be any polypeptide which induces an immune response. Administration of the fusion protein to a subject results in a cytotoxic T lymphocyte response being induced against the antigenic polypeptide provided within the fusion protein. The invention further extends to methods for the treatment of a disease condition in a subject using the fusion proteins of the invention.

The invention belongs to the technical field of biological pharmacy, and relates to a tumor targeting polypeptide-medicine coupling derivative, and a preparation method and application thereof. The tumor targeting polypeptide-medicine coupling derivative comprises targeting polypeptides, long effect polypeptides and medicine molecules, wherein the targeting polypeptides are connected onto the endC of the long effect polypeptides through flexible connecting peptides; fusion peptides are used as carriers of the medicine molecules; the medicine carriers and the long effect polypeptides in the fusion peptides are connected through chemical bonds; and the long effect polypeptides are polypeptide or protein structural domains having the affine mutual effects with human serum albumin. The tumortargeting polypeptide-medicine coupling derivative can be combined with the human serum albumin; the remaining half-life period in the blood circulation system can be obviously prolonged; the long-term effectiveness in the body is realized; the targeting and seepage into the tumor tissues or cells can be realized; then, free effect molecules are released in tumor tissue micro acid environments orin cells in through an acid hydrolysis mechanism; and a better anti-tumor efficiency is achieved.

The invention discloses an urea enzyme epitope fuse peptiolipid plastid vaccine to against pylorus bolt bacteria infection, which is characterized by the following: choosing fuse peptide of pylorus bolt bacteria urea enzyme B subunit and stick film adjuvant cholera morbus toxin B subunit as immunogen; coating the immunogen with liposome; producing the liposome vaccine. This liposome vaccine can evoke organism to generate special immune response and inhibit planting of pylorus bolt bacteria in stomach.

The present invention provides compositions for use as vaccines against the influenza virus, and rapid methods of producing such compositions. The composition include i) at least one peptide derived from an influenza virus, wherein the peptide is fused to a capsid protein derived from a plant virus forming a recombinant capsid fusion peptide and ii) at least one isolated antigenic protein or protein fragment derived from a human or avian influenza virus. The isolated antigenic protein or protein fragment derived from the human or avian influenza virus can be conjugated to the surface of the recombinant capsid fusion peptide.

PCT No. PCT/EP92/00089 Sec. 371 Date Nov. 2, 1992 Sec. 102(e) Date Nov. 2, 1992 PCT Filed Jan. 17, 1992 PCT Pub. No. WO92/13525 PCT Pub. Date Aug. 20, 1992The phospholipid bilayer contains at least one pharmaceutically active drug and comprises cell-specific markers on the membrane which have at least 90% biological activity when measured according to Luescher & Glueck, Antiviral Research 14, 39-50. In the membrane, the cholesterol content is preferably less than 2% by weight, the detergent content preferably less than 1 ppb. The vesicle diameter preferably is about 80 nm. the phospholipid in the membrane may comprise 70 to 95% by weight of phosphatidylcholine and preferably 10 to 20% by weight of phosphatidylethanolamine; preferably 6-8% by weight of a crosslinker, preferably of a sulfosuccinimidyl derivate, and at least one cell-specific fusion peptide are linked to the membrane. The vesicles are used for the preparation of pharmaceuticals against AIDS and carcinomas.

The invention relates to a tumor antigen prediction method based on a whole transcriptome. The tumor antigen prediction method includes the steps: respectively performing protein generation and peptide fragment interception of tumor-associated antigen, detection of tumor somatic mutation and corresponding mutant peptide fragment interception, generation of tumor-specific novel transcript and peptide fragment interception, and gene fusion detection and fusion peptide fragment interception in tumor tissues, according to the whole transcriptome sequencing data of tumor tissues and corresponding adjacent para-carcinoma tissues, obtaining tumor-associated antigen, tumor somatic mutation, tumor novel transcript, tumor-specific peptide fragment of gene fusion, calculating affinity of the obtainedtumor-specific peptide fragment and the HLA molecule and the amount of expression in each transcript, and based on the affinity value of the tumor-specific peptide fragment and the amount of expression TPM (transcripts per million) value, evaluating the level of the candidate tumor antigen. The invention also provides an application of the same. The tumor antigen prediction method based on a whole transcriptome and the application of the same are conductive to accurate calculation of the tumor antigen load, evaluation of immunological therapy effect, and tumor vaccine design of the later stage of service.